Bay Area startup Rain Therapeutics nabs $18M Series A to target lung cancer niche
A biotech laser focused on a subtype of non-small cell lung cancer has raised $18.4 million from San Francisco’s Biotechnology Value Fund and other investors.
The Series A cash will see Fremont, CA-based Rain Therapeutics through a Phase II study for its lead drug, tarloxotinib, in patients with EGFR and ErbB Exon 20 insertion mutated NSCLC, scheduled to begin in 2019. Perceptive Advisors, Auckland UniServices Limited’s Inventors Fund and other private investors also chipped in for the round, adding a large sum to the $1 million Rain banked late last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
